Evolus expands license for Estyme dermal fillers to Canada, Australia, New Zealand

What happened

Evolus, Inc. (Nasdaq: EOLS), a company that develops and markets aesthetic injectables, announced on August 4, 2026 that its subsidiary Evolus Pharma B.V. amended an existing agreement with Symatese Aesthetics S.A.S. The amendment expands the territory where Evolus has the exclusive right to sell and distribute Symatese's Estyme branded dermal fillers, adding Canada, Australia and New Zealand to the previously licensed regions.

The stock closed at $7.59 on August 4, up 2.4% from the prior close of $7.41.

Details of the agreement

The amendment modifies the License, Supply and Distribution Agreement originally signed December 20, 2023. Under the new terms, Evolus Europe gets exclusive commercialization and distribution rights for the full Estyme line of injectable hyaluronic acid gels in Canada, and in Australia and New Zealand combined. Hyaluronic acid gels are injectable dermal fillers used to add volume and smooth wrinkles; the Estyme brand is a product of Symatese.

Evolus Europe will pay Symatese $920,000 in upfront signing payments. Additional payments of up to $1.38 million are due upon receiving certain regulatory approvals in the new territories.

Symatese remains responsible for all development and regulatory work needed to obtain and maintain those approvals, covering its own costs.

The license for each new territory has a 15-year initial term starting from the first regulatory approval, and automatically renews for successive five-year periods. Other terms from the original 2023 agreement apply.

What this means

Evolus disclosed this amendment in a Form 8-K filed with the SEC. An 8-K is used to notify shareholders of material events that could affect the company's value. Items 1.01 and 7.01 indicate a material definitive agreement was entered and the company also issued a press release (furnished under Regulation FD, meaning it is not considered an official SEC filing for liability purposes).

The expansion gives Evolus access to three additional national markets for its portfolio of injectable aesthetic products. Canada, Australia and New Zealand are regulated markets for medical devices; Evolus will rely on Symatese to secure approvals. The upfront payment of $920,000 and potential milestone payments of $1.38 million are small relative to the company's market capitalization (around $470 million), but signal a modest expansion commitment.

Because the territory rights are exclusive and run for 15 years, this move adds a new potential revenue stream in markets where Evolus does not currently distribute Estyme. The original 2023 agreement already covered other regions; this filing reveals the specific new countries.